Success Story: NIW Approval for Research at the Cancer-Inflammation Interface

Client’s Testimonial:

 

"Thank you so much for your great effort and help.”

 


 

On July 8th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Research Scientist in the Field of Cancer Immunology (Approval Notice).

 


 

General Field: Cancer Immunology

 

Position at the Time of Case Filing: Research Scientist

 

Country of Origin: India

 

State of Residence at the Time of Filing: Tennessee

 

Approval Notice Date: July 8th, 2026

 

Processing Time: 3 months, 12 days (Premium Processing Requested)

 


 

Case Summary:

 

The client sought the assistance of North America Immigration Law Group (Chen Immigration Law Associates) to prepare an NIW petition based on a research program dedicated to understanding how inflammation influences cancer development and treatment response. As a research scientist, the client investigated immune signaling molecules to identify new therapeutic targets and improve the effectiveness of immunotherapies for cancer patients.

 

Our petition emphasized that the client's proposed endeavor was not limited to studying a single disease or treatment approach. Instead, it aimed to establish a broader scientific foundation for biomarker-driven therapeutics by integrating advanced molecular profiling, high-resolution imaging, and cellular analysis. We explained that a better understanding of the underlying interactions between the cellular microenvironment and disease progression could lead to earlier identification of clinically relevant biomarkers, more precise treatment selection, and improved patient outcomes across multiple oncological conditions. The proposed endeavor also aligned with national priorities promoting advances in biotechnology and precision medicine.

 

To demonstrate that the client was well positioned to carry this work forward, we presented evidence of a growing research career supported by strong academic training and measurable scientific contributions. The client published 4 peer-reviewed journal articles and 4 conference abstracts. At the time of filing, this work had received 149 citations, including one publication ranking among the top 0.1% most-cited Clinical Medicine papers for its publication year and two additional publications ranking among the top 1%. The client had also been invited to review manuscripts for a peer-reviewed scientific journal, reflecting recognition of expertise within the research community.

 

Following a Premium Processing request submitted on May 8th, 2026, USCIS approved the petition on July 8th, 2026, after 3 months and 12 days of processing. We congratulate the client on this successful NIW approval and look forward to future contributions that improve biomarker discovery, precision immunotherapy, and cancer care.